Measurement of bone metabolism markers and changes of bone mineral density in patients with bone and joint disease and fractures in perioperative period
10.3969/j.issn.2095-4344.2016.35.018
- VernacularTitle:骨关节病变及骨折患者围术期骨代谢标志物检测及骨密度变化
- Author:
Shihong LI
;
Yang LIU
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2016;20(35):5290-5295
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:The bone mineral density is a static parameter that reflects the bone mass in a relatively long time. If you want to know the dynamic changes of bone metabolism, bone metabolism markers should be evaluated.
OBJECTIVE:To explore changes of bone metabolism markers and bone mineral density during perioperative period in patients with spine and joint degeneration and osteoporotic fractures.
METHODS:We retrieved PubMed and Wanfang database for articles published from 2005 to 2016. The key words were“bone metabolic markers, bone mineral density, serum, urine”. Twenty-nine articles were analyzed according to inclusion and exclusion criteria.
RESULTS AND CONCLUSION:At present, bone formation markers commonly used in clinic mainly included bone alkaline phosphatase, osteocalcin, procol agen type I N-terminal peptide, and procol agen type I C-terminal peptide. Bone resorption markers included tartrate resistant acid phosphatase, col agen type I N-terminal telopeptide, col agen type I C-terminal telopeptide, deoxidation pyridinoline, pyridinoline, and hydroxyproline. Bone mineral density had little change, and bone resorption markers were elevated in patients with spine and joint degeneration and osteoporotic fractures, indicating active resorption. Increased bone formation markers in patients with fracture during perioperative period suggested that new bone formed in perioperative period of fracture. In the perioperative period, bone formation markers reduced and bone formation was inhibited in patients with bone degeneration. Increased bone resorption is more obvious in perioperative period in patients with bone and joint disease and fractures, which probably further aggravated the degree of osteoporosis, and should be treated by regular anti-osteoporosis therapy.
